Steven Frommeyer

Articles by Steven Frommeyer

Cross Q&A: The Memorial Sloan-Kettering Mavericks

ByXiaoli Mi, MD,Steven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD

May 27th 2022

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Outcome Determination for Adolescents and Young Adults with ALL

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD

May 27th 2022

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD,Reem Akel, MD

May 27th 2022

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD

May 23rd 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Cross Q&A: Team Moffitt Marrowvingians

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD

May 23rd 2022

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD

May 13th 2022

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

HyperCVAD in Frontline ALL

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Xiaoli Mi, MD,Varun Narendra, MD

May 13th 2022

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Use of Inotuzumab for ALL in the Frontline Setting

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Meghan Thompson, MD,Varun Narendra, MD,Xiaoli Mi, MD

May 6th 2022

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

BySteven Frommeyer,Nikesh Shah, MD,Somedeb Ball, MD,Reem Akel, MD,Varun Narendra, MD,Xiaoli Mi, MD,Meghan Thompson, MD

May 6th 2022

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

Latest Updated Articles

Cross Q&A: The Memorial Sloan-Kettering Mavericks
May 27th 2022
HyperCVAD in Frontline ALL
May 13th 2022
Use of Inotuzumab for ALL in the Frontline Setting
May 6th 2022
Outcome Determination for Adolescents and Young Adults with ALL
May 27th 2022
Cross Q&A: Team Moffitt Marrowvingians
May 23rd 2022
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
May 6th 2022

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)